Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 84

Results For "CAPA"

2452 News Found

AbbVie to acquire Capstan Therapeutics for $2.1 billion
Biotech | July 01, 2025

AbbVie to acquire Capstan Therapeutics for $2.1 billion

Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo


Indegene identified as leader in ISG's Provider Lens for life sciences digital services
News | July 01, 2025

Indegene identified as leader in ISG's Provider Lens for life sciences digital services

ISG acknowledged Indegene's strengths in implementing holistic creative workflows, interoperability via robust integration with tech ecosystems


Biocon Biologics expands insulin access in Malaysia
News | June 30, 2025

Biocon Biologics expands insulin access in Malaysia

Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served


Fredun Pharmaceuticals acquires One Pet Stop to foray into pet care market
Healthcare | June 30, 2025

Fredun Pharmaceuticals acquires One Pet Stop to foray into pet care market

The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028


Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr
News | June 29, 2025

Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr

Acquisition to be followed by merger; strengthens Torrent’s IPM market presence


Shukra Pharmaceuticals receives LoA from RMSCL
News | June 28, 2025

Shukra Pharmaceuticals receives LoA from RMSCL

The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan


European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME
Drug Approval | June 28, 2025

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME


Star Health Insurance partners with Medi Assist to transform claims through AI and Digital Innovation
News | June 27, 2025

Star Health Insurance partners with Medi Assist to transform claims through AI and Digital Innovation

Star Health Insurance is modernising its claims ecosystem to be future-ready


Ashland expands viatel bioresorbable polymers offering for medical devices
Medical Device | June 26, 2025

Ashland expands viatel bioresorbable polymers offering for medical devices

Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants


Sai Life Sciences commences commercial operation of 2nd phase in Bidar
News | June 23, 2025

Sai Life Sciences commences commercial operation of 2nd phase in Bidar

This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility